Abstract

Chemed will report results on April 23, 2026 Post Market; this preview outlines consensus revenue, margins and EPS expectations for the new quarter, reviews last quarter’s performance, and highlights institutional sentiment and key business drivers through the period from January 1, 2026 to April 16, 2026.

Market Forecast

Market models for Chemed’s current quarter point to total revenue of 649.82 million US dollars, an adjusted EPS of 5.30, and EBIT of 91.13 million US dollars, with year-over-year changes of 1.25%, -4.40%, and -9.99%, respectively; company-level metrics imply a gross profit margin trajectory in the mid-30s and net profit margin around the low teens, in line with the prior quarter. Main business trends suggest steady growth at the consolidated level, supported by resilient demand across hospice care and plumbing services. The segment with the most promising outlook this quarter is Roto‑Rooter, expected to benefit from sustained commercial and residential service activity, while VITAS continues to drive the larger revenue base.

Last Quarter Review

Chemed’s last reported quarter delivered revenue of 639.34 million US dollars, a gross profit margin of 35.22%, net profit attributable to the parent of 76.75 million US dollars with a net profit margin of 12.00%, and adjusted EPS of 6.42, with revenue down 0.10% year over year and adjusted EPS down 6.00% year over year. A notable financial highlight was quarter-on-quarter net profit growth of 19.48%, signaling improving profitability momentum into the new period. By business, VITAS contributed 418.76 million US dollars and Roto‑Rooter 220.58 million US dollars, with hospice remaining the primary revenue engine and services providing diversification and cash generation.

Current Quarter Outlook

Main business: Hospice care (VITAS)

VITAS remains Chemed’s largest revenue driver, anchoring more than half of consolidated sales. With revenue last quarter at 418.76 million US dollars and a stable gross margin base implied by the consolidated 35.22% result, the current quarter’s models anticipate modest year-over-year revenue expansion within the consolidated 1.25% growth outlook. Key operational variables in the quarter include hospice average daily census trends, labor utilization and wage inflation, and payer mix, all of which can influence unit economics and case intensity. Considering the forecasted decline in group EBIT and EPS, VITAS is likely balancing growth with ongoing cost normalization, indicating that margin expansion may be constrained near term despite stable top-line progress.

Most promising business: Roto‑Rooter

Within the diversified portfolio, Roto‑Rooter is positioned to capture incremental demand from both residential and commercial markets. The business generated 220.58 million US dollars last quarter, and near-term drivers include steady call volumes, pricing discipline, and franchise network leverage. The segment’s margin structure typically provides a buffer when healthcare-related costs fluctuate, making it a potential offset to hospice cyclicality. In the current quarter, Roto‑Rooter’s operational resiliency and service mix breadth provide a path for stable to slightly improving contribution, supporting consolidated earnings even as group-level EBIT and EPS forecasts soften year over year.

Stock price sensitivity this quarter

Share performance in this window is most sensitive to three metrics: the realized revenue trajectory relative to the 649.82 million US dollars estimate, EPS delivery versus the 5.30 forecast, and the direction of margins versus the prior quarter’s 35.22% gross and 12.00% net margins. Upside could emerge if hospice daily census and length-of-stay metrics outpace expectations and if labor costs moderate faster than modeled, lifting operating leverage. Conversely, any margin pressure from wage dynamics or payer mix shifts at VITAS, combined with softer ticket counts or weather disruptions at Roto‑Rooter, could reinforce the year-over-year EBIT and EPS declines embedded in models, weighing on sentiment.

Analyst Opinions

Across recent commentary surveyed through April 16, 2026, the balance of opinion is cautiously positive, with a tilt toward expectations of stable top-line growth and manageable margin pressure, yielding a majority bullish stance relative to bearish views. Analysts citing the forecast of 649.82 million US dollars in revenue and EPS of 5.30 emphasize the company’s consistent execution across both segments and the benefit of diversified cash flows. The constructive camp expects hospice volume stability and cost controls to keep earnings near forecast, while highlighting Roto‑Rooter as a dependable counterbalance if healthcare margins tighten. Overall, the majority outlook anticipates Chemed to deliver results broadly in line with current estimates, with the post‑report discussion likely centered on the direction of margins and the sustainability of census trends at VITAS.